McKesson, Oracle, Thoma Bravo among finalists to acquire Veradigm: report
Ariel Skelley
McKesson (NYSE:MCK) and Oracle (NYSE:ORCL) are among the finalists seeking to acquire electronic medical records company Veradigm (OTC:MDRX), Axios reported Sunday, citing sources.
According to the report, a deal is expected to top Veradigm’s $1B market cap due to the lower antitrust risk from the incoming Trump administration.
One source was quoted as saying that the companies and private-equity firm Thoma Bravo could possibly have asked for a small discount due to possible increased antitrust scrutiny due to their medical data holdings.
Axios reported that sources said Thoma Bravo was particularly interested due to its NextGen portfolio company.
The sources reportedly said that CVS Health (CVS) had looked at Veradigm but dropped out amid its own strategic review.
Axios reported that a deal is expected to be reached by Thanksgiving, the sources said.
Veradigm, McKesson, Oracle, and Thoma Bravo did not immediately respond to requests for comment by Seeking Alpha.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10